Technical Analysis for ARWR - Arrowhead Research Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 20.24 | -1.17% | -0.24 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Bearish Engulfing | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.17% | |
NR7 | Range Contraction | -1.17% | |
Multiple of Ten Bullish | Other | -1.17% | |
Up 3 Days in a Row | Strength | -1.17% | |
Earnings Movers | Other | -0.15% |
Alert | Time |
---|---|
Down 1% | 2 days ago |
60 Minute Opening Range Breakdown | 2 days ago |
Reversed from Up | 2 days ago |
50 DMA Resistance | 2 days ago |
Upper Bollinger Band Resistance | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 02/04/2025
Arrowhead Research Corporation Description
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Organ Systems Molecular Biology Infection Obesity Hepatitis B Gene Expression RNA Rna Interference Apoptosis Chronic Hbv Infection Chronic Hepatitis B Virus Rna Therapeutics Si RNA Small Interfering Rna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 36.72 |
52 Week Low | 17.05 |
Average Volume | 2,229,518 |
200-Day Moving Average | 22.61 |
50-Day Moving Average | 20.79 |
20-Day Moving Average | 19.72 |
10-Day Moving Average | 19.98 |
Average True Range | 1.10 |
RSI (14) | 51.69 |
ADX | 14.35 |
+DI | 29.78 |
-DI | 17.00 |
Chandelier Exit (Long, 3 ATRs) | 18.55 |
Chandelier Exit (Short, 3 ATRs) | 21.04 |
Upper Bollinger Bands | 21.35 |
Lower Bollinger Band | 18.09 |
Percent B (%b) | 0.66 |
BandWidth | 16.53 |
MACD Line | -0.01 |
MACD Signal Line | -0.10 |
MACD Histogram | 0.0968 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 22.79 | ||||
Resistance 3 (R3) | 23.04 | 22.44 | 22.37 | ||
Resistance 2 (R2) | 22.44 | 21.79 | 22.32 | 22.22 | |
Resistance 1 (R1) | 21.34 | 21.39 | 21.04 | 21.09 | 22.08 |
Pivot Point | 20.74 | 20.74 | 20.59 | 20.62 | 20.74 |
Support 1 (S1) | 19.64 | 20.09 | 19.34 | 19.39 | 18.40 |
Support 2 (S2) | 19.04 | 19.69 | 18.92 | 18.26 | |
Support 3 (S3) | 17.94 | 19.04 | 18.12 | ||
Support 4 (S4) | 17.69 |